Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00660335 | Safety and Efficacy of Synthetic Human Secretin-Enhanced MRCP in Subjects With Abnormalities of the Pancreas | PHASE3 | COMPLETED | 258 | — | — | Mar 1, 2008 | Oct 1, 2009 | Dec 3, 2009 | - | — |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| RG1068 (synthetic human secretin) | DRUG | Single-dose, IV infusion |
Inclusion Criteria: * History of pancreatitis * Medically stable * Able to give informed consent Exclusion Criteria: * Prior history of pancreatic resection * Prior history of pancreatic duct drainage procedure * Presence of a pancreatic stent * Unstable cardiovascular disease * Any contraindicat...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| CytoSorbents Corporation | CTSO | 1 | — | Undisclosed |
| Azienda Ospedaliera Universitaria Integrata Verona | VRNA | 1 | — | Undisclosed |